In a recent letter addressed to stockholders, Jaisim Shah, CEO and President of Scilex Holding Company, highlighted the significant accomplishments of the company in 2023 and provided a positive outlook for the upcoming year. This comes on the heels of favorable developments, such as an insurance coverage agreement for ELYXYB and the addition of ZTlido to the Medicaid Preferred Drug List in the State of Tennessee. These achievements not only solidify Scilex’s position as an innovative non-opioid pain management products provider but also have considerable implications for the company’s growth and future prospects.
ELYXYB Insurance Coverage Agreement:Scilex Holding Company announced its successful signing of an insurance coverage agreement with one of the top three national Pharmacy Benefit Managers (PBMs) for its Medicare population. This agreement potentially expands the coverage of ELYXYB, an essential non-opioid pain management product. By securing insurance coverage for ELYXYB, Scilex is likely to witness increased adoption and availability of this innovative solution, benefiting both patients and the company’s revenue stream.
ZTlido Included in Tennessee’s Medicaid Preferred Drug List:Adding to its achievements, Scilex Holding Company announced that the State of Tennessee included ZTlido, a lidocaine topical system, as a preferred agent on its Medicaid Preferred Drug List. This development is expected to dramatically improve access to ZTlido for approximately 1.5 million eligible patients between the ages of 19 to 64. As a preferred agent, ZTlido is likely to attract a larger patient market, leading to increased sales and revenue for Scilex. Additionally, this move signifies the recognition of ZTlido’s efficacy and potential to revolutionize pain management in the state.
2023 Accomplishments and Outlook for 2024:Scilex Holding Company’s CEO, Jaisim Shah, expressed pride in the company’s accomplishments in 2023. With the inclusion of ZTlido in Tennessee’s Medicaid Preferred Drug List and the agreement for ELYXYB insurance coverage, Scilex has made significant strides towards its goal of becoming a leading provider of non-opioid pain management solutions. As the new year unfolds, the company is well-positioned to forge ahead with its growth strategy. The anticipated revenue generation, driven by the expanded availability and coverage of key products, contributes to a positive outlook for 2024.
Conclusion:Scilex Holding Company’s achievements in 2023, including securing insurance coverage for ELYXYB and gaining preferred status for ZTlido in Tennessee’s Medicaid Preferred Drug List, demonstrate the company’s commitment to revolutionizing non-opioid pain management. These milestones are expected to have a substantial impact on the company’s growth, further establishing its position as an innovative leader in the industry. As Scilex enters 2024, the company’s proactive measures and strategic advancements set the stage for a promising and successful year ahead.
Comments